In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Corvus Pharmaceuticals Inc. Trade Record

NASDAQ:CRVS Corvus Pharmaceuticals Inc stock gains 18.39% Exit Jun 4, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart CRVS May 17, 2018, priceSeries
About Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that plan to initiate a Phase 1/1b clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
99.60
Entry Date
May 17, 2018
Entry Price
10.07
Sell Date
Jun 4, 2018
Sell Price
11.92
Net Gain
18.39%
Hold Time
11 Trading Days